Ascend Capital’s Ligand Pharmaceuticals LGND Stock Holding History

Ascend Capital’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-25,622	Closed	-$2.64M	–	204
2018 Q1	$2.64M	Buy	+25,622	New	+$2.53M	0.11%	152

Other funds holding LGND

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Ascend Capital's LGND Position: Q2 2018 in Review

Ascend Capital sold out of Ligand Pharmaceuticals (LGND) in Q2 2018, closing a stake of 25,622 shares — an estimated $2.64M sold.

Ascend Capital first reported a position in LGND in Q1 2018 and held it in 1 quarter. The position peaked at $2.64M in Q1 2018. 346 funds tracked by Wall St. Rank hold LGND as of Q2 2018.

Ascend Capital reported no remaining Ligand Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
Ascend Capital sold 25,622 Ligand Pharmaceuticals shares in Q2 2018, an estimated $2.64M.
Ascend Capital first reported a position in Ligand Pharmaceuticals in Q1 2018 and held it in 1 quarter.
Ascend Capital's Ligand Pharmaceuticals position peaked at $2.64M in Q1 2018.
346 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2018.

Based on Ascend Capital's 13F filing for Q2 2018, filed 13 Aug 2018.